Acquisition Announced
Biogen acquisition of Apellis Pharmaceuticals
US$5.6bn equity value
Announced 31 Mar 2026 · US$41.00 cash and scrip per share
Advisers
Apellis Pharmaceuticals
Target
- Financial adviser
- Legal adviser
Other advisers
- Financial adviser
- Target
- Apellis Pharmaceuticals
- Acquirer
- Biogen
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Pharma, Ophthalmology
In the league tables
Similar deals
- BioMarin acquisition of Amicus Therapeutics Dec 2025 · US$4.8bn · Biotech
- Eli Lilly and Company acquisition of Centessa Pharmaceuticals Mar 2026 · US$6.3bn · Biotech
- Vertex Pharmaceuticals acquisition of Crinetics Pharmaceuticals Jul 2026 · US$10bn · Biotech
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
- Servier acquisition of Day One Biopharmaceuticals Mar 2026 · US$2.5bn · Biotech
Sources
- 31 Mar 2026 Biogen’s $5.6 Billion Acquisition of Apellis cravath.com
- 3 Apr 2026 Tender offer communication (SC TO-C), Apellis Pharmaceuticals, Inc. sec.gov
- 6 Apr 2026 Target tender offer communication (SC14D9C), Apellis Pharmaceuticals, Inc. sec.gov
- 14 Apr 2026 Tender offer statement (SC TO-T), Apellis Pharmaceuticals, Inc. sec.gov
- 14 Apr 2026 Target response to tender offer (SC 14D9), Apellis Pharmaceuticals, Inc. sec.gov
- 14 May 2026 Lazard: UNITED STATES Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology lazard.com



